Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF 7147-IR-100 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemRecombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF
CompanyR&D Systems, a Bio-Techne Brand
Price $504.00Supplier Page View Company Product Page
Catalog Number7147-IR-100
SpeciesHuman
Source/Expression SystemCHO-derived Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF
Size100 ug
Molecule NameIL-13 R alpha 2
NCBI Full Gene Nameinterleukin 13 receptor subunit alpha 2
NCBI Gene AliasesIL13BP, CD213A2, IL-13R, CT19
FormatLyophilized from a 0.2 µm filtered solution in PBS
Purity>95%, by SDS-PAGE under reducing conditions and visualized by silver stain
Molecular WeightObserved: 75-95 kDa, reducing conditions
Theoretical: 64 kDa (monomer)
ApplicationsBioactivity
Conjugate/TagUnconjugated
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapyCell Stem CellFebruary 6, 2025Meghan Logun, Xin Wang, Yusha Sun, Stephen J. Bagley, Nannan Li, Arati Desai, Daniel Y. Zhang, MacLean P. Nasrallah, Emily Ling-Lin Ling-Lin Pai, Bike Su Oner, et al.AF647,BioLegend,Cat#: 388913; RRID: N/A Recombinant Human IL13Ra2 Protein Fc Chimera,R&D Systems,Cat#: 7147-IR-100; RRID: N/A Biotinylated Human EGFRvIII Protein,AcroBiosystems,Cat#: EGR-H82E0-25ug; RRID: N/A Rabbit

(2) Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim resultsNature medicineMay 1, 2024Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, Nabavizadeh A, Jarocha D, Martins R, Maloney E, et al.

(3) Bi-Specific Killer Cell Engager Enhances NK Cell Activity against Interleukin-13 Receptor Alpha-2 Positive GliomasCellsJune 25, 2023Pawlowski KD, Duffy JT, Tiwari A, Zannikou M, Balyasnikova IV.(ELISA) assay was used to determine the binding capacity of BiKE to human recombinant IL13Rα2 (Cat 7147-IR-100; R&D Systems). A 96-well plate was coated overnight at 4 °C with 1 μg/mL IL13Rα2 in PBS. The plate was

(4) Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with (89)Zirconium oxine for PET imagingJournal of translational medicineJune 7, 2023Leland P, Kumar D, Nimmagadda S, Bauer SR, Puri RK, Joshi BH.Waltham, MA). scFV-IL-13Rα2 expressing T cells were first incubated with IL-13R alpha 2Fc chimera (cat# 7147-IR-100, R&D Systems) after Biotinylating with Biotinylation kit (Cat# ab201796, abCam, Waltham, MA). Brilliant

(5) Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapyProceedings of the National Academy of Sciences of the United States of AmericaAugust 16, 2022Stern LA, Gholamin S, Moraga I, Yang X, Saravanakumar S, Cohen JR, Starr R, Aguilar B, Salvary V, Hibbard JC, et al.31.25 ng/well rhIL13Rα1-Fc chimera (catalog 146-IR-100, R&D Systems) or IL13Rα2-Fc chimera (catalog 7147-IR-100, R&D Systems). Supernatants were then evaluated for IFN-γ levels using the Legend Max ELISA kit (BioLegend,

(6) Trivalent CAR T cells overcome interpatient antigenic variability in glioblastomaNeuro-oncologyMarch 27, 2018Bielamowicz K, Fousek K, Byrd TT, Samaha H, Mukherjee M, Aware N, Wu MF, Orange JS, Sumazin P, Man TK, et al.

(7) Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against GlioblastomaMolecular therapy : the journal of the American Society of Gene TherapyJanuary 3, 2018Brown CE, Aguilar B, Starr R, Yang X, Chang WC, Weng L, Chang B, Sarkissian A, Brito A, Sanchez JF, et al.

(8) Cytokine induction of VCAM-1 but not IL13Rα2 on glioma cells: a tale of two antibodiesPloS oneJanuary 1, 2014Mahadev V, Starr R, Wright SL, Martinez C, Jensen MC, Barish ME, Forman SJ, Brown CE.

(9) Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastomaMolecular therapy : the journal of the American Society of Gene TherapyNovember 1, 2013Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, Zhang YJ, Baskin DS, Merchant FA, Brawley VS, et al.

Be the First to Write a Review!

Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF from R&D Systems, a Bio-Techne Brand

R&D Systems, a Bio-Techne Brand

Citations (9)

Reviews

Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map